These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 35731078)

  • 1. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
    Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™).
    Khamisy-Farah R; Damiani G; Kong JD; Wu JH; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(17):5448-5451. PubMed ID: 34533820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade.
    Sharif K; Omar M; Lahat A; Patt YS; Amital H; Zoabi G; Bragazzi NL; Watad A
    Front Pharmacol; 2023; 14():1271309. PubMed ID: 37954855
    [No Abstract]   [Full Text] [Related]  

  • 5. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
    Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
    Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967-2023: A comprehensive analysis of the international pharmacovigilance database.
    Lee S; Lee K; Park J; Jeong YD; Jo H; Kim S; Woo S; Son Y; Kim HJ; Lee K; Ha Y; Oh NE; Lee J; Rhee SY; Smith L; Kang J; Rahmati M; Lee H; Yon DK
    J Med Virol; 2024 Jul; 96(7):e29792. PubMed ID: 38993028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
    Lee S; Yang JW; Jung SY; Kim MS; Yon DK; Lee SW; Kang HC; Dragioti E; Tizaoui K; Jacob L; Koyanagi A; Salem JE; Kostev K; Lascu A; Shin JI; Kim JH; Smith L
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7390-7397. PubMed ID: 34919240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.
    Drucker AM; Ellis AG; Bohdanowicz M; Mashayekhi S; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Küster D; Siegels D; Schmitt J; Flohr C
    JAMA Dermatol; 2020 Jun; 156(6):659-667. PubMed ID: 32320001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO's VigiBase.
    Hirai E; Haruki T; Baba T; Miyazaki D
    Adv Ther; 2023 Sep; 40(9):3830-3856. PubMed ID: 37358706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports.
    Leitzen S; Dubrall D; Toni I; Stingl J; Christ P; Köberle U; Schmid M; Neubert A; Sachs B
    Paediatr Drugs; 2023 Mar; 25(2):203-215. PubMed ID: 36369590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

  • 15. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
    Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H
    Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
    Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
    Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
    Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
    Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
    Masuka JT; Khoza S
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.